SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

William Reed Business Media SAS (a William Reed Business Media group company), is a business-to-business publisher supplying strategically relevant news directly to the desktops of decision-makers in the science, cosmetics and food industries. The group runs innovative online marketing solutions for leading international industry providers.

Today, the company runs 19 highly targeted industry platforms and over 30 e-newsletters in industries such as food, beverage, nutritional supplements, cosmetics and pharmaceuticals.

Food & Beverage

FoodNavigator.com
FoodNavigator-USA.com
FoodNavigator-Asia.com
FoodAndDrinkEurope.com
FoodProductionDaily.com
FoodQualityNews.com
BakeryAndSnacks.com
BeverageDaily.com
ConfectioneryNews.com
DairyReporter.com
GlobalMeatNews.com

Nutrition

NutraIngredients.com
NutraIngredients-USA.com

Pharmaceuticals

in-PharmaTechnologist.com
Outsourcing-Pharma.com
BioPharma-Reporter.com

Cosmetics

CosmeticsDesign.com USA
CosmeticsDesign-Europe.com
CosmeticsDesign-Asia.com

Spotlight

Third time's a charm: Pfizer to buy Hospira for $17bn
breaking news

Third time's a charm: Pfizer to buy Hospira for $17bn

Pfizer has entered into a definitive merger agreement to buy Hospira for $17bn.

Vertellus buys antiretroviral API reagent plant from Dow

Vertellus buys antiretroviral API reagent plant from Dow

Specialty chemicals firm Vertellus will continue to supply antiretroviral drugmakers sodium borohydride following its takeover of a...

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm was hurt by weak US demand for the weight loss pill Qsymia, higher raw material prices...

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Pfizer must act fast to convince investors it can compete with Roche and Biogen Idec for a...

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

Researchers claiming Tamiflu cuts flu symptom duration and hospitalisations analysed less than half as many studies as...